Richard Champlin

5.0k total citations · 2 hit papers
55 papers, 3.6k citations indexed

About

Richard Champlin is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Richard Champlin has authored 55 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 15 papers in Genetics and 12 papers in Oncology. Recurrent topics in Richard Champlin's work include Hematopoietic Stem Cell Transplantation (24 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Acute Myeloid Leukemia Research (11 papers). Richard Champlin is often cited by papers focused on Hematopoietic Stem Cell Transplantation (24 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Acute Myeloid Leukemia Research (11 papers). Richard Champlin collaborates with scholars based in United States, United Kingdom and France. Richard Champlin's co-authors include M. Andreeff, Jennifer L. Dembinski, Maria da Graça Cabreira-Hansen, Matus Studeny, Claudia Zompetta, F. Marini, B. Nebiyou Bekele, Robert Peter Gale, Mary M. Horowitz and Estella Whimbey and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Richard Champlin

53 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase

1988 692 citations Robert Peter Gale, Mary M. Horowitz et al. Annals of Internal Medicine profile →
Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

2004 670 citations Matus Studeny, F. Marini et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Champlin United States	26	2.0k	1.1k	951	802	493	55	3.6k
H M Lazarus United States	29	1.7k 0.9×	1.3k 1.2×	1.1k 1.1×	531 0.7×	662 1.3×	66	3.8k
RE Champlin United States	28	2.7k 1.3×	1.0k 1.0×	869 0.9×	912 1.1×	407 0.8×	50	3.4k
Koichi Miyamura Japan	34	2.3k 1.2×	749 0.7×	665 0.7×	1.1k 1.4×	530 1.1×	204	3.7k
Francesco Lanza Italy	33	2.1k 1.1×	1.0k 1.0×	822 0.9×	920 1.1×	804 1.6×	159	3.8k
Russell K. Brynes United States	35	1.0k 0.5×	1.1k 1.0×	734 0.8×	755 0.9×	425 0.9×	105	3.3k
K Lilleby United States	24	2.8k 1.4×	1.6k 1.5×	639 0.7×	840 1.0×	332 0.7×	38	3.7k
R. Willemze Netherlands	35	1.7k 0.8×	1.0k 1.0×	1.6k 1.6×	856 1.1×	1.0k 2.1×	129	4.3k
Taner Demirer Türkiye	31	2.2k 1.1×	1.2k 1.1×	512 0.5×	763 1.0×	338 0.7×	101	3.2k
Colleen Delaney United States	32	2.9k 1.5×	1.1k 1.0×	1.2k 1.2×	1.2k 1.4×	797 1.6×	116	4.3k
Giuseppe Bandini Italy	29	2.4k 1.2×	797 0.8×	795 0.8×	1.1k 1.4×	502 1.0×	134	3.4k

Countries citing papers authored by Richard Champlin

Since Specialization

Citations

This map shows the geographic impact of Richard Champlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Champlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Champlin more than expected).

Fields of papers citing papers by Richard Champlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Champlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Champlin. The network helps show where Richard Champlin may publish in the future.

Co-authorship network of co-authors of Richard Champlin

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Champlin. A scholar is included among the top collaborators of Richard Champlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Champlin. Richard Champlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shigle, Terri Lynn, Chitra Hosing, Amin Alousi, et al.. (2025). Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica. 110(8). 1798–1807.

Ledesma, Celina, Nitin Jain, Priti Tewari, et al.. (2024). Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 2810–2810. 1 indexed citations

Ramdial, Jeremy, Laura Di Clemente, Pinaki P. Banerjee, et al.. (2024). Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies. Blood. 144(Supplement 1). 4841–4841.

Kebriaei, Partow, Timothy Madden, X. Wang, et al.. (2012). Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplantation. 48(1). 26–31. 10 indexed citations

Eapen, Mary, Sergio Giralt, Mary M. Horowitz, et al.. (2004). Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplantation. 34(8). 721–727. 152 indexed citations

Studeny, Matus, F. Marini, Jennifer L. Dembinski, et al.. (2004). Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents. JNCI Journal of the National Cancer Institute. 96(21). 1593–1603. 670 indexed citations breakdown →

Champlin, Richard, et al.. (2002). Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transplant Infectious Disease. 4(1). 3–9. 57 indexed citations

Kim, Young Sil, Sergej Konoplev, Filippo Montemurro, et al.. (2001). HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.. PubMed. 7(12). 4008–12. 33 indexed citations

Champlin, Richard, Nadeem Q. Mirza, J. Gajewski, et al.. (2001). Adenovirus Infections in Adult Recipients of Blood and Marrow Transplants. Clinical Infectious Diseases. 32(6). 871–876. 210 indexed citations

10.

Champlin, Richard & Estella Whimbey. (2001). Community respiratory virus infections in bone marrow transplant recipients: The M.D. Anderson Cancer Center experience. Biology of Blood and Marrow Transplantation. 7(12). 8S–10S. 52 indexed citations

11.

Buchholz, Thomas A., Susan L. Tucker, Richard A. Moore, et al.. (2000). Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. International Journal of Radiation Oncology*Biology*Physics. 46(2). 337–343. 11 indexed citations

12.

Hortobagyi, Gabriel N., Aman U. Buzdar, Richard L. Theriault, et al.. (2000). Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. JNCI Journal of the National Cancer Institute. 92(3). 225–233. 126 indexed citations

13.

Kornblau, Steven M., Al B. Benson, Robert B. Catalano, et al.. (2000). Management of Cancer Treatment–Related Diarrhea. Journal of Pain and Symptom Management. 19(2). 118–129. 69 indexed citations

14.

Champlin, Richard, I. Khouri, Steven M. Kornblau, et al.. (1999). ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY. Hematology/Oncology Clinics of North America. 13(5). 1041–1057. 38 indexed citations

15.

Bojko, Peter, Jeane P. Hester, April Durett, et al.. (1998). Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors. Journal of Clinical Apheresis. 13(1). 7–15. 9 indexed citations

16.

Khouri, Issa F., Donna Przepiorka, Koen van Besien, et al.. (1997). Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft‐versus‐host disease. British Journal of Haematology. 97(2). 466–473. 77 indexed citations

17.

Gajewski, James, et al.. (1989). Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome.. Journal of Clinical Oncology. 7(11). 1637–1645. 96 indexed citations

18.

Cain, Gary & Richard Champlin. (1989). Long-term complete chimerism and stable hematopoiesis in Beagles after fetal liver hematopoietic stem cell transplantation. American Journal of Veterinary Research. 50(8). 1282–1284. 6 indexed citations

19.

Winston, Drew J., L J Eron, Monto Ho, et al.. (1988). Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. The American Journal of Medicine. 85(2). 147–151. 24 indexed citations

20.

Champlin, Richard, W.E. Kastenberg, & Robert Peter Gale. (1988). Radiation Accidents and Nuclear Energy: Medical Consequences and Therapy. Annals of Internal Medicine. 109(9). 730–744. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact